Home » Uncategorized » Tarceva May Improve Survival From Lung Cancer

Patients whose advanced lung cancers bear the EGFR mutation survive two to three times longer if given initial treatment with Tarceva, a Chinese study suggests.

A Japanese study reported earlier this year suggests that a similar drug, Iressa, may also be most effective if given prior to standard chemotherapy.

Patients taking Tarceva suffered far fewer side effects of therapy than those on standard chemo.

Not all lung cancers carry the EGFR mutation. But those that do are sensitive to two drugs that target the EGFR enzyme: Genentech’s Tarceva, and AstraZeneca’s Iressa.

A raft of clinical trials are under way exploring how to capitalize on these findings. Most of them are using Tarceva or Iressa in combination with different agents.

Via: WebMD.com

Outsmart cancer

  • "Cancer does not have to be a death sentence"
  • WATCH

    Let’s Find Out How To Be Cancer Proof!